Anshul Gupta
@DrAnshul_Gupta
Followers
42
Following
50
Media
2
Statuses
11
Consultant Medical Oncology, Max SuperSpeciality Hospital Vaishali
Joined December 2021
1 more week to vote for @ASCO elections, all stellar candidates!Excited to see @neerajaiims running for nominating committee:so humble & awesome leader! @OncoAlert @OncBrothers @spsutkaMD @mtsiatas @MichalisLiontos @g_mountzios @curijoey @GPentheroudakis
https://t.co/FIg4lL01qX
1
11
23
Great work @nihanthy @tuttsakhil
Pleased to share our short commentary on the current adjuvant therapy landscape in RCC @nihanthy
https://t.co/8ul4Ty800C
1
0
4
Excited to see our own, dynamic clinician and researcher, Dr Neeraj Agarwal running for ASCO nominating seat. Throwing our full weight behind him @batraatulonc @DrNikitaMehra @DrJasminPorwall @DharamKaushik5 @drshubhamsahni @RanjitKSMD @dr_rajapramanik @nihanthy @garg_h
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
0
6
9
More options in bladder cancer
Treatment after EVP in bladder cancer is undefined. Izalontamab brenitecan (HER2/3 TROP2 ADC) has good activity in bladder+lung cancer. A global randomised phase III has started enrolment 👉 Iza Bren alone vs platinum chemo in previously treated pts (including EVP). @OncoAlert
0
0
0
Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science
4
62
127
🎉 GU-ONCOCON 2025 was a tremendous success! Huge thanks to our keynote speakers: Prof. Neeraj Agrawal, Prof. Yüksel Ürün, Dr.Shilpa Gupta, Professor Yüksel Urun, Dr. Dharam Kaushik, and Dr. Ravindran Kanesvaran Their inspiring talks offered invaluable insights into GU oncology
0
3
17
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo
@PCFnews @urotoday @OncoAlert
Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: https://t.co/o5jjU6Tc9g & https://t.co/HQUNZxA52q
@urotoday @OncoAlert @PCFnews 👇
18
69
178
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG - unresponsive NMIBC with CIS with or without papillary tumors. Also known as TAR-200: this gemcitabine intravesical system is
4
42
125
Excited to host @neerajaiims @shilpaonc @DharamKaushik5 @DrYukselUrun @ravikanesvaran at GUONCOCON2025 in Delhi… a true MDT meeting in urology cancers….also involves hands on robotic workshop in partial nephrectomy…. keep following and don’t forget to register …with
4
5
21
Looking forward to hosting the second edition of our annual oncology meeting
1
1
3